A Spontaneous Nonhuman Primate Model of Myopic Foveoschisis.
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
03 Jan 2023
03 Jan 2023
Historique:
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
26
1
2023
Statut:
ppublish
Résumé
Foveoschisis involves the pathologic splitting of retinal layers at the fovea, which may occur congenitally in X-linked retinoschisis (XLRS) or as an acquired complication of myopia. XLRS is attributed to functional loss of the retinal adhesion protein retinoschisin 1 (RS1), but the pathophysiology of myopic foveoschisis is unclear due to the lack of animal models. Here, we characterized a novel nonhuman primate model of myopic foveoschisis through clinical examination and multimodal imaging followed by morphologic, cellular, and transcriptional profiling of retinal tissues and genetic analysis. We identified a rhesus macaque with behavioral and anatomic features of myopic foveoschisis, and monitored disease progression over 14 months by fundus photography, fluorescein angiography, and optical coherence tomography (OCT). After necropsy, we evaluated anatomic and cellular changes by immunohistochemistry and transcriptomic changes using single-nuclei RNA-sequencing (snRNA-seq). Finally, we performed Sanger and whole exome sequencing with focus on the RS1 gene. Affected eyes demonstrated posterior hyaloid traction and progressive splitting of the outer plexiform layer on OCT. Immunohistochemistry showed increased GFAP expression in Müller glia and loss of ramified Iba-1+ microglia, suggesting macro- and microglial activation with minimal photoreceptor alterations. SnRNA-seq revealed gene expression changes predominantly in cones and retinal ganglion cells involving chromatin modification, suggestive of cellular stress at the fovea. No defects in the RS1 gene or its expression were detected. This nonhuman primate model of foveoschisis reveals insights into how acquired myopic traction leads to phenotypically similar morphologic and cellular changes as congenital XLRS without alterations in RS1.
Identifiants
pubmed: 36689233
pii: 2785304
doi: 10.1167/iovs.64.1.18
pmc: PMC9896856
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18Subventions
Organisme : NEI NIH HHS
ID : P30 EY012576
Pays : United States
Organisme : NIH HHS
ID : P51 OD011107
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY032238
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY031108
Pays : United States
Références
Prog Retin Eye Res. 2012 May;31(3):195-212
pubmed: 22245536
Mol Vis. 2006 Aug 10;12:892-901
pubmed: 16917482
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Retina. 2010 Apr;30(4):623-8
pubmed: 20394112
Mol Biol Cell. 2017 Aug 1;28(16):2178-2189
pubmed: 28615319
Hum Mutat. 2016 Mar;37(3):235-41
pubmed: 26555599
Am J Ophthalmol. 2007 Mar;143(3):455-62
pubmed: 17222382
Arch Ophthalmol. 1999 Jun;117(6):821-3
pubmed: 10369597
Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3806-11
pubmed: 15452092
Immunogenetics. 2019 Sep;71(8-9):531-544
pubmed: 31321455
Am J Ophthalmol. 2002 Jun;133(6):794-800
pubmed: 12036671
Adv Exp Med Biol. 2014;801:309-16
pubmed: 24664712
Br J Ophthalmol. 1995 Jul;79(7):653-7
pubmed: 7662629
Hum Gene Ther. 2021 Jul;32(13-14):667-681
pubmed: 33019822
J Clin Invest. 2019 Feb 1;129(2):863-874
pubmed: 30667376
Sci Rep. 2019 Aug 7;9(1):11459
pubmed: 31391523
Vis Neurosci. 2005 Sep-Oct;22(5):561-8
pubmed: 16332266
Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3620-8
pubmed: 15452069
Am J Ophthalmol. 1999 Oct;128(4):472-6
pubmed: 10577588
BMC Ophthalmol. 2017 Sep 8;17(1):166
pubmed: 28886700
Am J Ophthalmol. 2006 Sep;142(3):497-500
pubmed: 16935601
Transl Vis Sci Technol. 2021 May 3;10(6):7
pubmed: 34111251
Mutat Res. 2007 May 1;618(1-2):149-62
pubmed: 17292925
Hum Mutat. 2011 Aug;32(8):894-9
pubmed: 21520341
Proc Natl Acad Sci U S A. 2016 May 10;113(19):5287-92
pubmed: 27114531
Exp Eye Res. 2018 Mar;168:69-76
pubmed: 29352993
Sci Rep. 2016 Jan 29;6:20118
pubmed: 26823236
Exp Eye Res. 2021 Nov;212:108754
pubmed: 34506802
Invest Ophthalmol Vis Sci. 2007 Feb;48(2):891-900
pubmed: 17251492
Int Ophthalmol. 2020 Nov;40(11):2931-2948
pubmed: 32632619
Taiwan J Ophthalmol. 2015 Apr-Jun;5(2):56-62
pubmed: 29018668
Mol Vis. 2020 Apr 01;26:235-245
pubmed: 32280188
Gene Ther. 2022 Aug;29(7-8):431-440
pubmed: 34548657
Arch Ophthalmol. 1986 Apr;104(4):576-83
pubmed: 3954665
Retina. 2005 Jan;25(1):69-74
pubmed: 15655444
Am J Ophthalmol. 2008 May;145(5):902-8
pubmed: 18342829
Prog Retin Eye Res. 2022 Mar;87:100999
pubmed: 34390869
Invest Ophthalmol Vis Sci. 2020 Feb 7;61(2):32
pubmed: 32084273
Invest Ophthalmol Vis Sci. 2016 Oct 01;57(13):5764-5771
pubmed: 27792810
Prog Retin Eye Res. 2009 Nov;28(6):423-51
pubmed: 19660572
Ophthalmology. 2022 May;129(5):542-551
pubmed: 34822951
Am J Hum Genet. 2016 Oct 6;99(4):877-885
pubmed: 27666373
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Annu Rev Vis Sci. 2020 Sep 15;6:149-169
pubmed: 32936734
Mol Ther Methods Clin Dev. 2020 Aug 08;18:869-879
pubmed: 32953936
Jpn J Ophthalmol. 2008 Jul-Aug;52(4):269-276
pubmed: 18773264
Nat Commun. 2019 Dec 17;10(1):5743
pubmed: 31848347
Sci Rep. 2017 Nov 3;7(1):15013
pubmed: 29101353
Eye (Lond). 2009 Feb;23(2):356-61
pubmed: 18064059
Eye (Lond). 2015 May;29(5):593-601
pubmed: 25744445
Am J Ophthalmol. 2020 Sep;217:152-161
pubmed: 32360335
Front Cell Neurosci. 2017 Aug 08;11:232
pubmed: 28848397
J Cell Mol Med. 2017 Apr;21(4):768-780
pubmed: 27995734
Curr Protoc Hum Genet. 2013 Jan;Chapter 7:Unit7.20
pubmed: 23315928
Invest Ophthalmol Vis Sci. 2001 Mar;42(3):816-25
pubmed: 11222545
Hum Mol Genet. 2000 Jul 22;9(12):1873-9
pubmed: 10915776
Ophthalmology. 2022 Feb;129(2):191-202
pubmed: 34624300
Nat Genet. 1997 Oct;17(2):164-70
pubmed: 9326935